[Approaches to prevention of the middle to late phase adverse drug reactions in chemotherapy].
This is a review of the prevention of middle to late phase adverse drug reactions in chemotherapy. The development of clinical practice guidelines for cancer chemotherapy is being promoted recently. The guidelines for the prevention of adverse drug reactions are also necessary to achieve the best results from chemotherapy. A feature of middle to late phase adverse reactions is that almost all reactions are accumulative toxicities depending on the total dose of drug. Moreover, if they happen, there is no standard therapy to control the toxicity and only supportive care can be provided. Therefore, prevention and early detection of the toxicity is of utmost importance. It is necessary that all clinicians should have the knowledge of how to control these toxicities, and treat the patients appropriately on the basis of that knowledge.
Maeda
Yoshiharu
Y
Dept. of Chemotherapy, Tokyo Metropolitan Komagome Hospital.
Sasaki
Tsuneo
T
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000175:diagnosis; D001761:Bleomycin / Q000009:adverse effects; D002066:Busulfan / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D019983:Guideline Adherence; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D009336:Necrosis; D009369:Neoplasms / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D011014:Pneumonia / Q000139:chemically induced / Q000517:prevention & control*; D014750:Vincristine / Q000009:adverse effects
D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D002066:Busulfan